Evodiamine suppresses non-small cell lung cancer by elevating CD8⁺ T cells and downregulating the MUC1-C/PD-L1 axis.

ABSTRACT:

Background

Accumulating evidence showed that regulating tumor microenvironment plays a vital role in improving antitumor efficiency. Programmed Death Ligand 1 (PD-L1) is expressed in many cancer cell types, while its binding partner Programmed Death 1 (PD1) is expressed in activated T cells and antigen-presenting cells. Whereas, its dysregulation in the microenvironment is poorly understood. In the present study, we confirmed that evodiamine downregulates MUC1-C, resulting in modulating PD-L1 expression in non-small cell lung cancer (NSCLC).

Methods

Cell viability was measured by MTT assays. Apoptosis, cell cycle and surface PD-L1 expression on NSCLC cells were analyzed by flow cytometry. The expression of MUC1-C and PD-L1 mRNA was measured by real time RT-PCR methods. Prote

SUBMITTER: Jiang ZB 

PROVIDER: S-EPMC7677782 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature